ApotheTech is an early stage mobile health development company focused on medication safety and health literacy, jointly owned and formed with former pharmacy students and the Texas A&M Health Science Center.
Astero BioPharma LLC, formed to commercialize the research of Drs. Raimund Ober and Elizabeth Sally Ward, addresses the development of biotherapeutics for the treatment of cancer and autoimmune diseases.
Atumida Inc. is developing technologies that treat and reverse hemorrhagic shock. Founded in 2009, Atumida was a spin-off from Scott & White research in Temple and maintains formal relationships with the hospital system, Texas A&M, the University of Texas MD Anderson Cancer Center and Viral Genetics Inc. While Atumida’s technology belongs to Scott & White, Texas A&M maintains equity due to its contribution to initial business planning. Universities tend to focus on commercializing technology licensed from within their own institutions, making the Atumida a unique animal for Texas A&M.
Bio-MedPoint seeks to improve the health in America and globally by early detection of coronary artery disease. By lowering the cost and improving the efficacy of detection, Bio-MedPoint helps medical experts better serve their patients.
BLAST Therapeutics Inc. is a specialty, development stage biomaterials company focused on developing materials that accelerate bone repair and regeneration to improve patient care. The technology, developed at The Institute for Regenerative Medicine at Texas A&M Health Science Center provides a platform technology based on the identification and characterization of two classes of bone marrow stem cells, as well as unique methods to condition these cells to increase their propensity for making bone.
Co-founded by Texas A&M University scientists in 2017 and headquartered in College Station, TX, Bondwell Technologies is commercializing a revolutionary biomaterial-based platform technology. This technology allows the use of the natural ability of proteins, molecular tools required for every natural process, to impact multiple fields including: energy, environment, and medicine.
Craniotech ACR Devices, co-founded by Dr. Lynne Opperman out of Texas A&M’s College of Dentistry, focuses on the development of devices pertaining to bone reconstruction, specifically a new bone transport reconstruction plate (BTRP). The company has been awarded several STTR and SBIR grants to build and test prototypes of the device.
ECM Biosurgery, LLC, a medical device company, located in Houston, Texas is utilizing technology developed at Texas A&M Health Science Center to actively pursue its research efforts on the application of a proprietary technology platform, Designer Collagens, to develop a portfolio of products to address surgical needs in human and animal health.
Fortis Biosciences is an early stage biotechnology company dedicated to developing their microbiota-metabolite and method technology to target inflammatory disorders and infectious colitis in a broad sense, formed from technology developed at Texas A&M College of Medicine and College of Engineering.
framergy, founded in 2011, focuses on clean energy and clean air. Framergy has created precise molecule traps, opening up a new avenue for the design of absorbents with ultra-high surface area, and permanent porosity. framergy also oversees the commercialization of groundbreaking innovations in metal-organic-frameworks (MOF) for industrial uses.
Global BioDiagnostics, Inc. (GBDC) was formed to commercialize the Rapid TB Diagnostic Assay, a technology from the Texas A&M University Health Science Center College of Medicine. This technology would be the world’s first easy-to-use, low-cost tuberculosis
diagnostic, which also provides the accuracy of bacteriological culture while being as simple as smear microscopy.
Inhibitex, a clinical-stage biopharmaceutical company dedicated to the development of innovative products that can treat or prevent serious infections, primarily focuses on the development of nucleotide/nucleoside analogs for the treatment of hepatitis C virus (HCV). Inhibitex was acquired in February 2012 by Bristol-Myers Squibb. It was the first life sciences company that spun out of Texas A&M to go public, and, in the process, the company raised $300 million.